🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
SYK
NYSE
🇺🇸 US
Stryker Corporation
Healthcare
55Score
DipBuster Score™
$275.56
+$5.55 (+2.06%)
Live price · Source: Yahoo
52-Week Position
$267.00
7% of range
$392.55
Beta
0.768
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.768
52W High$392.55
52W Low$267.00
DipBuster Brief
Key signals at a glance
Zone: Strong Buy
Bullish
Near 52-Week Low — Wide Margin of Safety
At 7% of its annual range the stock is near its floor, offering value investors a cushion before fundamentals need to re-rate.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position7% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.768
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Stryker Corporation (SYK), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-08-21 | Crotty Dylan Bram | SELL | 441 |
| 2026-08-01 | Montagnino Kimberly Ann | SELL | 155 |
| 2026-08-01 | King Debra | SELL | 533 |
| 2026-08-01 | Fletcher Robert S | SELL | 94 |
| 2026-08-01 | Fink M Kathryn | SELL | 111 |
| 2026-06-01 | Stiles Spencer S | SELL | 1,607 |
| 2026-05-28 | Fletcher Robert S | SELL | 125 |
| 2026-05-28 | Fletcher Robert S | SELL | 258 |
| 2026-05-28 | Fletcher Robert S | SELL | 1,067 |
| 2026-05-28 | Fletcher Robert S | SELL | 2,809 |
Valuation
P/E RatioN/A
Market CapN/A
Beta0.768
Dividend/yrNone
52W High$392.55
52W Low$267.00
52-Week Range
$267.00Now$392.55
7% through annual range
From 52W High−29.8%
From 52W Low+3.2%
📖 Plain English Summary
Stryker Corporation is at 7% of its 52-week range. Beta 0.768 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for SYK
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — SYK
Heuristic · balance sheet, insider filings, price data, academic research
Stryker Corporation — DipBuster Score 55/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Stryker Corporation free
Add SYK to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Hargreaves Lansdown
UK's #1 investment platform. ISA, SIPP, GIA. FCA regulated since 1981.
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
37/25
Momentum & Volume
13/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
60
/100 · STRONG
dip depth
25/25
oversold rsi
22/25
mean reversion
13/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
🟢
Dip Signal
DipBuster Score: 55/100
📈
Strong recent momentum — price and volume trending in the right direction.
Company Profile
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replace…
Sector
Healthcare
Market
🇺🇸 US
CEO
Kevin A. Lobo
Staff
56,000 employees
Website